| Patent application number | Description | Published |
| 20090216300 | METHOD AND APPARATUS FOR LIGHT-ACTIVATED DRUG THERAPY - A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer. | 08-27-2009 |
| 20100121252 | NON-INVASIVE VASCULAR TREATMENT SYSTEMS, DEVICES, AND METHODS OF USING THE SAME - An energy treatment system to treat a patient includes an energy delivery device having a plurality of energy emitters used in combination with an energy activatable drug. A mask can be used to define a treatment area. Energy from the energy emitters passes through an optical window of the mask to activate a cosmetically and/or therapeutically effective amount of the activatable drug at the target site to bring about a desired change of tissue, for example, to reduce visibility of one or more blood vessels, while energy from the energy emitters directed outside of the target site is blocked by the mask. | 05-13-2010 |
| 20100305436 | SYSTEMS, DEVICES, AND METHODS FOR PHOTOACTIVE ASSISTED RESECTION - A method and system is used to locate tissue for removal during a resection. The system includes a container that holds a photoactivatable agent capable of binding with unwanted tissue at a treatment site, a light source, and a viewing device. The light source is adapted to continuously output light that causes fluorescence of the photoactivatable agent in unwanted tissue. The system provides fluorescence-enhanced viewing of the treatment site through the viewing device. The viewing device has a filter that filters out light from the light source that is reflected from the treatment site while allowing a fluorescence emission from the photoactivatable agent to pass therethrough to each eye of the user. The light from the light source and the fluorescence emission are in different regions of the energy spectrum. | 12-02-2010 |